Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Pharmacological Intervention in Depression After Traumatic Brain Injury
This study has been completed.
Sponsors and Collaborators: Virginia Commonwealth University
Department of Education
Information provided by: Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT00205491
  Purpose

The purpose of this study is to determine if treatment with venlafaxine reduces symptoms of depression in persons with traumatic brain injury.


Condition Intervention Phase
TBI (Traumatic Brain Injury)
Drug: Venlafaxine
Phase IV

MedlinePlus related topics: Depression Traumatic Brain Injury
Drug Information available for: Venlafaxine Venlafaxine hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Official Title: Pharmacological Intervention in Depression After Traumatic Brain Injury (A Research Study Within the Traumatic Brain Injury Model System)

Further study details as provided by Virginia Commonwealth University:

Primary Outcome Measures:
  • Score on the Hamilton Rating Scale for Depression (Ham-D)at 12 weeks.

Secondary Outcome Measures:
  • Scores on cognitive and psychomotor tests at 12 weeks.
  • Scores on a satisfaction with life measure and a functional measure at 12 weeks.

Estimated Enrollment: 100
Study Start Date: October 2004
Study Completion Date: September 2007
Detailed Description:

The study evaluates the benefits of a promising antidepressant medication for the treatment of persons with traumatic brain injury (TBI) and major depressive disorder (MDD). The study is a randomized, double-blind, placebo-controlled trial of venlafaxine (a serotonin and norepinephrine reuptake inhibitor, also known as Effexor). Venlafaxine has been well established in the treatment of MDD in healthy individuals and is a recommended depression treatment agent for persons with TBI. By using a rigorous scientific methodology, this study will be an important first step in advancing the treatment of depression in this population beyond general impressions to proven treatments.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have a documented traumatic brain injury (TBI), defined as damage to brain tissue caused by an external mechanical force as evidenced by: loss of consciousness due to brain trauma, or post traumatic amnesia (PTA), or skull fracture, or objective neurological findings that can be reasonably attributed to TBI on physical examination or mental status examination.
  • Age 18 years or older
  • At least three months postinjury
  • Presence of major depressive disorder (MDD), as defined by Structured Clinical Interview for DSM-IV (SCID) interview
  • Hamilton Depression Rating Scale (Ham-D) scores of 18 or greater on two consecutive evaluations (screening and baseline)

Exclusion Criteria:

  • Individuals under 18 years of age
  • Pregnancy, as determined by urine pregnancy screen
  • Prisoners
  • Individuals who are institutionalized
  • Individuals who are not cognitively capable of completing the SCID interview and the Ham-D
  • Unstable medical condition, defined as any significant medical condition likely to require hospitalization during the study period, or requiring adjustment in medications in the past month
  • Active suicidality
  • Severe depression that, in the investigator's professional opinion, will likely require hospitalization during the study time period
  • Diagnosis of bipolar disorder, as defined by SCID interview
  • Diagnosis of schizophrenia or other psychotic disorder, as defined by SCID interview, other than major depression with psychotic features
  • Active drug or alcohol abuse within the past 3 months, as defined by SCID interview
  • Dysphagia sufficient to preclude use of oral medications
  • Known hypersensitivity to venlafaxine
  • Use of monamine oxidase inhibitors (MAOI) within the past month
  • Treatment with antidepressant medication within the past 3 months
  • Concomitant administration of medications that interact with venlafaxine to a clinically significant degree
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00205491

Locations
United States, Virginia
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
Virginia Commonwealth University
Department of Education
Investigators
Principal Investigator: Jeffrey S. Kreutzer, PhD Virginia Commonwealth University
  More Information

Virginia Commonwealth University Traumatic Brain Injury Model System  This link exits the ClinicalTrials.gov site

Study ID Numbers: H133A02051602, H133A020516
Study First Received: September 12, 2005
Last Updated: October 23, 2007
ClinicalTrials.gov Identifier: NCT00205491  
Health Authority: United States: Food and Drug Administration

Keywords provided by Virginia Commonwealth University:
depression after brain injury
traumatic brain injury
Venlafaxine

Study placed in the following topic categories:
Craniocerebral Trauma
Depression
Wounds and Injuries
Central Nervous System Diseases
Disorders of Environmental Origin
Trauma, Nervous System
Depressive Disorder
Brain Diseases
Serotonin
Behavioral Symptoms
Mental Disorders
Venlafaxine
Mood Disorders
Brain Injuries

Additional relevant MeSH terms:
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Nervous System Diseases
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Uptake Inhibitors
Pharmacologic Actions
Serotonin Agents
Therapeutic Uses
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on January 16, 2009